156 related articles for article (PubMed ID: 9105872)
1. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.
Mansbach RS; Brooks EN; Chen YL
Eur J Pharmacol; 1997 Mar; 323(1):21-6. PubMed ID: 9105872
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the hypothalamus-pituitary-adrenal axis in antidepressant activity of corticotropin-releasing factor subtype 1 receptor antagonists in the rat learned helplessness test.
Takamori K; Kawashima N; Chaki S; Nakazato A; Kameo K
Pharmacol Biochem Behav; 2001; 69(3-4):445-9. PubMed ID: 11509203
[TBL] [Abstract][Full Text] [Related]
3. Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats.
Takamori K; Kawashima N; Chaki S; Nakazato A; Kameo K
Life Sci; 2001 Aug; 69(11):1241-8. PubMed ID: 11521748
[TBL] [Abstract][Full Text] [Related]
4. The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats.
Nakagawa Y; Sasaki A; Takashima T
Eur J Pharmacol; 1999 Sep; 381(1):1-7. PubMed ID: 10528127
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
Overstreet DH; Keeney A; Hogg S
Eur J Pharmacol; 2004 May; 492(2-3):195-201. PubMed ID: 15178365
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats.
Lu L; Liu D; Ceng X
Eur J Pharmacol; 2001 Mar; 415(2-3):203-8. PubMed ID: 11275000
[TBL] [Abstract][Full Text] [Related]
7. Repeated treatment with nitric oxide synthase inhibitor attenuates learned helplessness development in rats and increases hippocampal BDNF expression.
Stanquini LA; Biojone C; Guimarães FS; Joca SR
Acta Neuropsychiatr; 2018 Jun; 30(3):127-136. PubMed ID: 29151391
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the CRF
Wróbel A; Serefko A; Szopa A; Rojek K; Poleszak E; Skalicka-Woźniak K; Dudka J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):769-774. PubMed ID: 28429110
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Nielsen DM; Carey GJ; Gold LH
Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
11. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity.
Lundkvist J; Chai Z; Teheranian R; Hasanvan H; Bartfai T; Jenck F; Widmer U; Moreau JL
Eur J Pharmacol; 1996 Aug; 309(2):195-200. PubMed ID: 8874139
[TBL] [Abstract][Full Text] [Related]
12. Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats.
Wang J; Fang Q; Liu Z; Lu L
Psychopharmacology (Berl); 2006 Mar; 185(1):19-28. PubMed ID: 16374599
[TBL] [Abstract][Full Text] [Related]
13. Effects of CP-154,526 on responding during extinction from cocaine self-administration in rats.
Gurkovskaya O; Goeders NE
Eur J Pharmacol; 2001 Nov; 432(1):53-6. PubMed ID: 11734187
[TBL] [Abstract][Full Text] [Related]
14. Hypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats.
Raone A; Cassanelli A; Scheggi S; Rauggi R; Danielli B; De Montis MG
Neuroscience; 2007 Jun; 146(4):1734-42. PubMed ID: 17481824
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression.
Ferguson SM; Brodkin JD; Lloyd GK; Menzaghi F
Psychopharmacology (Berl); 2000 Oct; 152(3):295-303. PubMed ID: 11105940
[TBL] [Abstract][Full Text] [Related]
16. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
17. Role of brain arachidonic acid cascade on central CRF1 receptor-mediated activation of sympatho-adrenomedullary outflow in rats.
Yokotani K; Murakami Y; Okada S; Hirata M
Eur J Pharmacol; 2001 May; 419(2-3):183-9. PubMed ID: 11426840
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: involvement of NPY Y1 receptors.
Goyal SN; Upadhya MA; Kokare DM; Bhisikar SM; Subhedar NK
Brain Res; 2009 Apr; 1266():45-53. PubMed ID: 19254701
[TBL] [Abstract][Full Text] [Related]
19. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
Chaki S; Nakazato A; Kennis L; Nakamura M; Mackie C; Sugiura M; Vinken P; Ashton D; Langlois X; Steckler T
Eur J Pharmacol; 2004 Feb; 485(1-3):145-58. PubMed ID: 14757135
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of chronic antidepressant treatment on shuttle box escape deficits induced by uncontrollable stress.
Valentine G; Dow A; Banasr M; Pittman B; Duman R
Psychopharmacology (Berl); 2008 Nov; 200(4):585-96. PubMed ID: 18604599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
